Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 143 of the 143 references it cites were found in a registry or an index.

Clinical lessons learned from the first leg of the CAR T cell journey

Majzner, Robbie G., Mackall, Crystal L. · 2019 · Nature Medicine

Abstract

Chimeric antigen receptor (CAR) T cell therapy for B cell malignancies has surpassed expectations, driving an ever-expanding number of clinical trials and the first US Food and Drug Administration approvals of cell therapies for the treatment of cancer. This experience has illuminated some generalizable requirements for CAR T cell efficacy as well as the interplay between disease biology and clinical outcomes. Major CAR intrinsic variables affecting T cell behavior have been defined, and mechanisms of tumor resistance are increasingly understood. Here, we review the clinical experience with CAR T cells amassed to date, including but not limited to B cell malignancies, emphasizing factors associated with efficacy, resistance and major barriers to success. We also discuss how these insights are driving next-generation clinical trials, including those in solid tumors.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41591-019-0564-6

Cites

143 of 143 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 143 references

Research works printed but not linked: 2

  1. Schuster, S. J. et al. Primary analysis of Juliet: a global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma. Blood 130, 577 (2017).
  2. Fousek, K. et al. Targeting primary pre-B cell acute lymphoblastic leukemia and CD19-negative relapses using trivalent CAR T cells. Blood 130, 4614 (2017).

Cited by

See all 636

Metadata

Authors
Majzner, R. G., & Mackall, C. L.
Affiliations
Stanford Medicine (US)
Corresponding author
Mackall, Crystal L.
Venue
Nature Medicine
Published
2019-09
Volume
25
Issue
9
Pages
1341-1355
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W2973021197
Cited by
636
References
143
Citations by year
2026: 63 · 2025: 81 · 2024: 106 · 2023: 95 · 2022: 105 · 2021: 90 · 2020: 87 · 2019: 7
FWCI
6.91
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Nature Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Virginia and D.K. Ludwig Fund for Cancer Research
  • St. Baldrick’s Foundation (SU2C534 AACR-DT-27-17)
  • EIF | Stand Up To Cancer
  • Hyundai Motor Group | Hyundai Motor America | Hyundai Hope On Wheels
Topics
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
CAR T-cell therapy, CAR T-cell efficacy, B-cell malignancies, tumor resistance mechanisms, clinical trial design, solid tumors
MeSH terms
Antigens, Neoplasm, Humans, Neoplasms, T-Lymphocytes, United States, United States Food and Drug Administration, Immunotherapy, Adoptive, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical lessons learned from the first leg of the CAR T cell journey. https://app.cochat.ai/papers/10.1038/s41591-019-0564-6
The paper
Majzner, R. G., & Mackall, C. L. (2019). Clinical lessons learned from the first leg of the CAR T cell journey. Nature Medicine. https://doi.org/10.1038/s41591-019-0564-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.